AUG
28

Interim dividend for the six months ended 30 June 2025

AUG
28

Interim Results Announcement For the six months ended 30 June 2025

AUG
28

List of Directors and Their Role and Function

AUG
18

POSITIVE PROFIT ALERT

AUG
14

DATE OF BOARD MEETING

JUL
25

COMPLETION OF PLACING OF NEW SHARES UNDER THE GENERAL MANDATE

JUL
18

PLACING OF NEW SHARES UNDER THE GENERAL MANDATE

JUL
17

THE GROUP'S PRODUCT AMOXICILLIN SODIUM AND CLAVULANATE POTASSIUM FOR INJECTION PASSED THE CONSISTENCY EVALUATION

JUL
10

FDA APPROVAL OF IND FOR UBT37034 INJECTION

JUN
30

Special dividend for the year ended 31 December 2024

JUN
30

Final dividend for the year ended 31 December 2024

JUN
27

PAYMENT OF 2024 FINAL DIVIDEND AND SPECIAL DIVIDEND

JUN
25

POLL RESULTS OF THE 2025 ANNUAL GENERAL MEETING

JUN
20

RECEIVED UPFRONT PAYMENT FROM NOVO NORDISK FOR EXCLUSIVE LICENSE AGREEMENT OF UBT251

APR
29

NOTICE OF ANNUAL GENERAL MEETING

APR
15

THE GROUP'S PRODUCT CEFOTAXIME SODIUM FOR INJECTION PASSED THE CONSISTENCY EVALUATION

APR
07

VOLUNTARY ANNOUNCEMENT PROPOSED SHARE BUY-BACK UNDER GENERAL MANDATE

MAR
26

Special dividend for the year ended 31 December 2024

MAR
25

Final dividend for the year ended 31 December 2024

MAR
24

2024 ANNUAL RESULTS ANNOUNCEMENT

MAR
24

VOLUNTARY ANNOUNCEMENT EXCLUSIVE LICENSE AGREEMENT WITH NOVO NORDISK

MAR
21

UPDATED INFORMATION ON THE GROUP'S PRODUCT LIRAGLUTIDE INJECTION

MAR
21

UPDATED INFORMATION ON THE GROUP'S PRODUCT POLYVINYL ALCOHOL EYE DROPS

MAR
10

DATE OF BOARD MEETING

MAR
07

THE GROUP'S PRODUCT CEFTRIAXONE SODIUM FOR INJECTION PASSED THE CONSISTENCY EVALUATION

MAR
03

FDA APPROVAL OF IND FOR UBT251 INJECTION ON INDICATION OF CKD

JAN
22

APPROVAL FOR CLINICAL TRIAL OF UBT251 INJECTION ON INDICATION OF CHRONIC KIDNEY DISEASE

JAN
03

List of Directors and Their Role and Function